Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial of Argatroban for heparin resistance in critically ill patients
2012-000487-23Phase 2Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of argatroban in heparin resistance and venous thromboembolism (VTE), sponsored by Medical University of Innsbruck. Primary endpoint: Proportion achieving prophylactic aPTT range at 6–8 hours. Started Apr 2012; status: completed.
02
Drugs
argatroban
03
Conditions
heparin resistancevenous thromboembolism (VTE)
Beyond the preview
Go deeper on 2012-000487-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000487-23.